The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous conditions” will be published in the peer-reviewed journal “The Prostate”. The link to the article will be made available during March when the article has been published.
The aim of the study was to investigate the diagnostic value of the AroCell TK 210 ELISA together with free PSA, pro PSA and PHI in differentiating prostate cancer from benign urological conditions. This study was performed in collaboration with Ljubljana University Medical Centre and the Maribor University Medical Centre, Ljubljana.
“We are delighted with the promising results in this scientific study, which supports that the AroCell TK 210 ELISA can be a valuable tool in prostate cancer management”, says Michael Brobjer, AroCell CEO.
For more information:
Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Michael Brobjer, February 25, 2019 at 08:30.
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.
For more information; www.arocell.com